This activity was originally broadcast live at the 2022 Asembia Specialty Pharmacy Summit.
Program Description
Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease characterized by abnormally thick or enlarged heart muscle. Current treatments manage and prevent exacerbations of HCM symptoms, but research into HCM pathophysiology has led to the development of targeted therapies addressing the hypercontractility and underlying disease process. Patients with HCM experience substantial symptoms, the most concerning of which is sudden cardiac death, that negatively impact the patient’s overall quality of life and contribute to increased hospitalizations and costs of care. The pending approval of a first-in-class cardiac myosin inhibitor has the potential to improve patients’ health status and will open important avenues for pharmacists to facilitate access to this agent. This program will review treatment guidelines and safety and efficacy data for existing and emerging treatment modalities in the care of patients with HCM. As integral members of the health care team, it is imperative that pharmacists are knowledgeable about the challenges associated with the management of HCM as well as efficacy and safety data for emerging new therapies that treat the underlying causes to improve clinical outcomes for patients.
Target audience: Managed care pharmacists, health system pharmacists, and specialty pharmacists
Type of activity: Application
Release date: May 10, 2022
Expiration date: May 10, 2023
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Document the pathophysiology, incidence, and risk factors for hypertrophic cardiomyopathy (HCM) as well as the associated comorbidities and impact on patient health-related quality of life
- Examine current guidelines recommended and the efficacy and safety data of standard and novel therapies for the treatment and management of HCM
- Employ measures to identify and address gaps in HCM care
- Determine the role of the pharmacist in making clinical recommendations and in educating patients about treatments for HCM
Ty J. Gluckman, MD, MHA, FACC, FAHA
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence St. Joseph Health
Portland, Oregon
John Lindsley, PharmD, BCPS, BCCCP
Clinical Pharmacy Specialist
Johns Hopkins Hospital
Baltimore, Maryland
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-221-H01-P. The activity is available for CE credit through May 10, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Faculty
Ty J. Gluckman, MD, MHA, FACC, FAHA, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Premier Healthcare
Stock/Shareholder: Doximity
John Lindsley, PharmD, BCPS, BCCCP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff— Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Michelle C. Carlson, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.
Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms